Welcome to our dedicated page for Poseida Therapeutics news (Ticker: $PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Poseida Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Poseida Therapeutics's position in the market.
Astellas Pharma Inc. and Poseida Therapeutics, Inc. have entered into a research collaboration and license agreement to develop novel allogeneic CAR-T cell therapies in oncology. The partnership will leverage Poseida's proprietary allogeneic CAR-T platform and Xyphos' ACCELTM technology to create innovative convertibleCAR® programs targeting solid tumors. Under the agreement, Xyphos will reimburse Poseida for research costs and be responsible for product development and commercialization. Poseida will receive an upfront payment of US $50 million, with potential milestone and contingency payments totaling up to US $550 million, along with tiered royalties. The collaboration aims to address unmet medical needs in oncology and expand Astellas' portfolio with cutting-edge CAR-T cell therapies.
